Genzyme's Clolar fails to gain support of FDA panel

09/2/2009 | Reuters

Genzyme did not get support from an FDA advisory panel to market pediatric leukemia drug Clolar to adults with acute myeloid leukemia. In a 9-3 vote, the panel advised the company to conduct a randomized trial of Clolar to provide "an evidence-based justification" that the product is more effective than other treatments.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ